Fireside Chat - 41st Annual J.P. Morgan Healthcare Conference



Dr. Albert Bourla, DVM, PhD,
Chairman & CEO

Monday, January 9, 2023

Forward-Looking Statements and Other Notices

This presentation includes forward-looking statements that are subject to substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. We may include forward-looking statements about, among other topics, our anticipated operating and financial performance; reorganizations; business plans, strategy and prospects; expectations for our product pipeline, in-line products and product candidates, including anticipated regulatory submissions, data read-outs, study starts, approvals, launches, clinical trial results and other developing data, revenue contribution and projections, pricing and reimbursement, potential market dynamics and size, growth, performance, timing of exclusivity and potential benefits; strategic reviews, capital allocation objectives, dividends and share repurchases; plans for and prospects of our acquisitions, dispositions and other business development activities; our ability to successfully capitalize on growth opportunities and prospects; manufacturing and product supply; our efforts to respond to COVID-19, including our COVID-19 products; our expectations regarding the impact of COVID-19 on our business, operations and financial results; and other statements about our business, operations and financial results. Among other things, statements regarding revenue and earnings per share growth; the development or commercial potential of our product pipeline, in-line products, product candidates and additional indications or combinations, including expected clinical trial protocols, the timing of the initiation and progress of clinical trials and data read-outs from trials; the timing for the submission of applications for and receipt of regulatory approvals; the timing of product launches; expected profile and labeling; potential revenue; expected breakthrough, best or first-in-class or blockbuster status or expected market entry of our medicines or vaccines; the regulatory landscape; and the competitive landscape are forward-looking and are estimates that are subject to change and subject to clinical trial and regulatory success, availability of supply, competitive and market dynamics and other risks, assumptions and uncertainties.

These statements may be affected by underlying assumptions that may prove inaccurate or incomplete, and are subject to unknown risks, uncertainties and other factors that may cause actual results to differ materially from past results, future plans and projected future results. As forward-looking statements involve significant risks and uncertainties, caution should be exercised against placing undue reliance on such statements. Additional information regarding these and other factors can be found in Pfizer's Annual Report on Form 10-K for the fiscal year ended December 31, 2021 and its subsequent reports on Form 10-Q, including in the sections thereof captioned "Risk Factors" and "Forward-Looking Information and Factors That May Affect Future Results", as well as in our subsequent reports on Form 8-K, all of which are filed with the U.S. Securities and Exchange Commission and available at www.sec.gov and www.pfizer.com. Potential risks and uncertainties also include global economic and/or geopolitical instability, foreign exchange rate fluctuations and inflationary pressures and the impact of COVID-19 on our sales and operations, including impacts on employees, manufacturing, supply chain, marketing, research and development and clinical trials. The forward-looking statements in this presentation speak only as of the original date of this presentation and we undertake no obligation to update or revise any of these statements.

Today's presentation is intended for the investor community only; it is not intended to promote the products referenced herein or otherwise influence healthcare prescribing decisions. Definitive conclusions cannot be drawn from cross-trial comparisons or anticipated data as they may be confounded by various factors and should be interpreted with caution. All trademarks in this presentation are the property of their respective owners.

Paxlovid and emergency uses of the Pfizer-BioNTech COVID-19 Vaccine or the Pfizer-BioNTech COVID-19 Vaccine, Bivalent (Original and Omicron BA.4/BA.5), have not been approved or licensed by the FDA. Paxlovid has not been approved, but has been authorized for emergency use by the U.S. Food and Drug Administration (FDA) under an Emergency Use Authorization (EUA), for the treatment of mild-to-moderate COVID-19 in adults and pediatric patients (12 years of age and older weighing at least 40 kg [88 lbs]) with positive results of direct SARS-CoV-2 viral testing, and who are at high-risk for progression to severe COVID-19, including hospitalization or death. Emergency uses of the Pfizer-BioNTech COVID-19 Vaccine and the Pfizer-BioNTech COVID-19, Bivalent have been authorized by the FDA under an EUA to prevent COVID-19 in individuals aged 6 months and older. The emergency uses are only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of the medical product during the COVID-19 pandemic under Section 564(b)(1) of the FFDCA unless the declaration is terminated or authorization revoked sooner. Please see the EUA Fact Sheets at www.covid19oralrx.com and www.cvdvaccine-us.com.

Pfizer Non-COVID Potential Revenue Projections Based on Internal Expectations

For illustrative purposes only and not intended to be at scale. All values at constant exchange rates. Preliminary, subject to change, and subject to, among other risks, assumptions and uncertainties, clinical trial, regulatory and commercial success and availability of supply.



[1] Assumes 2022 non-COVID revenues at mid-point of guidance (~$44B) and 2022-2025 CAGR of 6%. Excludes 2022-2025 BD.
[2] Internal expected negative LOE impact from products with a 2021 total revenue base of $18B as shown on slide 4.
[3] Internal 2030 risk-adjusted revenue expectations for NME and new indications launches as shown on first two sections of slide 5
[4] Risk-adjusted 2030 revenue goal from BD deals
[5] Potential 2030 risk-adjusted revenues for new product launches as shown on slide 6

Key Products Included in the Expected ~$17 Billion in LOE Revenue Declines from 2025-2030

Product	2021 WW Revenues *($ millions)*	2021 U.S. Revenues *($ millions)*	2021 Dev. EU Revenues *($ millions)*	Year of Expected U.S. LOE	Year of Expected EU LOE
Eliquis	$5,970	$3,160	$1,520	2026*	2026
Inlyta	$1,002	$599	$181	2025	2025
Ibrance	$5,437	$3,418	$1,044	2027	2028
Xeljanz	$2,455	$1,647	$308	2025	2028
Xtandi	$1,185	$1,185	N/A	2027	N/A
Vyndaqel	$2,015	$909	$572	2024 (2028 pending PTE)	2026

* Date is based on the composition of matter patent. See Pfizer's 2021 Annual Report on Form 10-K filed with the U.S. Securities and Exchange Commission for more information about potential scenarios that could affect the timing of generic entry in the U.S.
PTE: Patent Term Extension LOE: Loss of Exclusivity

New Launches / Co-promotions and Potential Product Launches[1]

Product Candidate	Anticipated Indication	Expected Launch
New Molecular Entity (NME) Launches		
Ngenla (Ex-US)	Growth Hormone Deficiency	✓ 2022
Ritlecitinib	Alopecia Areata	2023
Elranatamab	Triple Class Relapsed or Refractory (Resistant to immunomodulators, proteasome inhibitors, and anti-CD38 therapy) Multiple Myeloma	2023
RSV Adults (60+)	Prevention of RSV-associated LRTI in adults >60 years	2023*
RSV Maternal	Prevention of RSV-associated LRTI in infants (via maternal immunization)	2023*
Pentavalent Meningococcal Vaccine	Prevention of meningococcal infection by serogroups ABCWY	2023*
Abrilada	Adalimumab Biosimilar	2023
mRNA flu Vaccine	Influenza	2024*
New Indications		
Myfembree	Endometriosis	✓ August 2022 (Pfizer co-promote)
COVID-19 vaccine BA.4/BA.5 variant	COVID-19	✓ September 2022
Cibinqo	Atopic Dermatitis Adolescent	2023
Braktovi/Mektovi	Lung Cancer (PHAROS)	2023
Talzenna (Talazoparib) + Xtandi (enzalutamide)	Metastatic castration resistant prostrate cancer (TALAPRO2)	2023
Xtandi	nmCSPC (EMBARK)	2023
Prevnar 20 Peds	Prevention of invasive pneumococcal disease, otitis media -Pediatric	2023*
Recently Announced Business Development Deals		
Nurtec ODT/Vydura	Acute treatment of Migraine and prevention of episodic Migraine	✓ August 2022 (Pfizer promotion)[2]
Zavegepant (intranasal)	Acute treatment of Migraine	2023
Oxbryta	Sickle cell disease	✓ October 2022 (with merger close)
Etrasimod	Ulcerative Colitis	2023

Note: Expected timing; all dates are preliminary, subject to change, and subject to clinical trial and regulatory success and availability of supply
* Estimated FDA decision; subject to regulatory approval, ACIP and MMWR to follow
[1] Over the next 18 months, we expect to have up to 19 new products or indications in the market – including the five for which we have already begun co-promotion or commercialization last year
[2] Through a standalone detailing arrangement

Additional Pipeline Potential Launches Through 2030 – Selected Examples

Product Candidate	Anticipated Indication(s)	Expected Potential Launch
New Molecular Entity (NME) Launches		
Danuglipron or PF'1532 (oral GLP1s)	Type 2 Diabetes, Obesity	>2024
Anti-IFN-β Antibody (PF'3859)	Dermatomyositis, Polymyositis	>2024
COVID / Influenza mRNA Combination Vaccine[1]	COVID-19 & Influenza prevention	>2024
Lyme Disease Vaccine (PF'405)	Lyme disease prevention	>2024
mRNA Shingles Vaccine[1]	Shingles (VZV) prevention	>2024
HemA GTx	Hemophilia A gene therapy	>2024
HemB GTx	Hemophilia B gene therapy	>2024
DMD GTx	Duchenne Muscular Dystrophy gene therapy	>2024
Sasanlimab	Non-muscle invasive bladder Cancer	>2024
marstacimab	Treatment of Hem A / Hem B	>2024
ARV-471	ER+/HER2- BC	>2024
TTI-622 (PF'801)	Hematological malignancies	>2024

Note: Expected timing; all dates are preliminary, subject to change, and subject to clinical trial and regulatory success and availability of supply

[1] In collaboration with BioNTech; and for COVID influenza combination, pending agreement between the partners

Fortifying our Long-Term Growth Plans – as presented on Dec. 12

*Illustrative**



*For illustration purposes only and not intended to be to scale. All values at constant exchange rates.
[1] Excludes 2022-2025 BD and 2022+ Launches
[2] Midpoint of expected negative LOE impact of $16B-$18B from 2025-2030.
[3] Risk-adjusted 2030 revenue goal from recent and new BD deals
[4] Internal 2030 risk-adjusted revenue expectations for NME and new indications launches as shown on slide 5
Note: Preliminary, subject to change, and subject to, among other risks, assumptions and uncertainties, clinical trial, regulatory and commercial success and availability of supply.